Summary
Merck & Co., Inc. reported solid financial performance for the fiscal year ending December 30, 2018, with total sales reaching $42.3 billion, a 5% increase over the previous year. This growth was primarily driven by strong sales in the oncology segment, notably from Keytruda, and robust performance in vaccines, particularly Gardasil/Gardasil 9. The Animal Health division also contributed positively to the overall revenue increase. The company demonstrated a commitment to innovation through continued investment in its research and development pipeline, focusing on key areas like immuno-oncology. Merck also actively pursued business development opportunities, including strategic collaborations and acquisitions, to enhance its portfolio and future growth prospects. The company returned significant capital to shareholders through dividends and share repurchases, reflecting its financial strength and confidence in its strategic direction. Despite facing ongoing pricing pressures and generic competition in certain product lines, Merck's diversified business segments and strong product pipeline position it for continued success.
Financial Highlights
53 data points| Revenue | $42.29B |
| Cost of Revenue | $13.51B |
| Gross Profit | $28.79B |
| R&D Expenses | $9.75B |
| SG&A Expenses | $10.10B |
| Interest Expense | $772.00M |
| Net Income | $6.22B |
| EPS (Basic) | $2.34 |
| EPS (Diluted) | $2.32 |
| Shares Outstanding (Basic) | 2.66B |
| Shares Outstanding (Diluted) | 2.68B |
Key Highlights
- 1Total sales increased by 5% to $42.3 billion in 2018, driven by strong performance in oncology (Keytruda), vaccines (Gardasil/Gardasil 9), and animal health.
- 2Keytruda sales significantly increased, reaching $7.2 billion in 2018, up from $3.8 billion in 2017, underscoring its importance as a growth driver.
- 3The company expanded its pipeline through collaborations and acquisitions, notably a strategic collaboration with Eisai for Lenvima and the acquisition of Viralytics.
- 4Research and development expenses remained substantial at $9.8 billion, reflecting continued investment in innovation and pipeline development.
- 5Merck returned $14.3 billion to shareholders in 2018 through dividends and share repurchases, demonstrating a commitment to shareholder value.
- 6The company faced continued pricing pressures globally and the impact of generic and biosimilar competition on certain established products, such as Zetia and Vytorin.
- 7The cyber-attack experienced in 2017 had a residual impact on sales in 2018, although it was less significant than in the prior year.